Merus pulls forward target date for solid tumor data, reiterates intent to file IPO

Nick Paul Taylor

has shaved months off the on which it expects to release from a Phase I/II trial of its lead bispecific antibody in HER2-expressing tumors. The Dutch immuno-oncology player provided the new timeline in an update to the paperwork it filed ahead of a planned Nasdaq IPO.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS